Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value Peer-spectives
Filter by Topic
ASCO’s Value Framework
Commentary
Employers’ Perspective
Letter to our Readers
Oncologist–Patient Communication
Patient Communication
Patient Perspective
Payer’s Perspective
Practice Management
Testimonials
The Patient Perspective
Value in Oncology
Value Propositions
VBCC Perspectives
NIH Awards $10.5 Million to New Technologies for the Study of Molecular Genes
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has awarded $10.5 million to 10 researchers to develop technologies that will assist research on millions of genomic elements that play a role in determining what genes are expressed, and at what levels in different cells.
Read Article
New Collaboration to Enhance Personalized Cancer Drug Development
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
Genomic Health announced it has formed an alliance with OncoMed Pharmaceuticals to support the development of DNA-sequencing technologies in the search for diagnostic biomarkers that could identify patients who will best benefit from targeted drugs currently in development by OncoMed.
Read Article
Oncologists Should Weigh “Value” in Their Clinical Decisions
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
A recent survey of US and Canadian oncologists explored how they perceive cost-effectiveness of the new and costly cancer treatments, and whether providers are considering value questions of quality versus cost in their clinical decisions.
Read Article
UK Researcher Charges NICE of Misapprehending Value of Costly Cancer Drugs
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Professor Jonathan Waxman, of Imperial College London, an expert in prostate cancer who founded the Prostate Cancer Charity in England and helped garner support for cancer treatment, has denounced the refusal of the UK National Institute for Health and Clinical Excellence (NICE) to approve the 2 new and expensive prostate cancer drugs approved last year in the United States, saying that NICE "has overregulated and proscribed drugs that offer real advances to people with cancer.
Read Article
Prostate Cancer Foundation Promotes Innovation in Young Investigators
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
The Prostate Cancer Foundation (PCF) is expanding its efforts to encourage innovation in prostate cancer research.
Read Article
Online Genetic Testing Registry New Tool from NIH
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
An online tool launched by the National Institutes of Health (NIH) will help patients, providers, and researchers navigate the rapidly growing landscape of genetic testing, many of them associated with cancer therapy.
Read Article
Despite Lack of Value, Many Providers Recommend Ovarian Cancer Screening
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Results of a new survey of primary care physicians (PCPs) show that 1 in 3 PCPs believe that ovarian cancer screening is safe and effective, contrary to current evidence. The survey was published in the February 7, 2012, issue of
Annals of Internal Medicine
.
Read Article
Cancer Center Launches Personalized Medicine Institute
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Moffitt Cancer Center in Tampa, FL, has announced it is launching its Personalized Medicine Institute to advance the fight against cancer, and implementing the promise of personalized cancer care medicine by focusing on innovative biotechnology with its biotechnology subsidiary M2Gen.
Read Article
Novel Biologics Will Reshape Cancer Therapy by 2018, Affordability Key Challenge
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Researchers at Espicom Business Intelligence, a medical and pharmaceutical market analysis company, predict that the development of novel biologic approaches to drug therapy will bring "a sea change" to the approach to cancer therapy, by focusing on controlling solid tumors and the introduction of new drugs that target new pathways.
Read Article
Diagnosing Melanoma Early May Soon Be Easier: MelaFind Gets Approvable Letter
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
On September 26, 2011, the FDA issued an approvable letter to Mela Sciences, the manufacturer of MelaFind, an investigational diagnostic device for early melanoma.
Read Article
Page 12 of 16
7
8
9
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma